Bioxytran Interview at the Emerging Growth Conference
BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB:BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran CCO Michael Sheikh will be discussing the latest peer reviewed journal article and snippet of Bioxtyran’s Long Covid presentation on the Emerging Growth Conference on April 5, 2023 at 10:50am EST. Investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released. Please submit your questions in advance to Questions@EmergingGrowth.com.
Related news for (BIXT)
- Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
- Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
- Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens